Zobrazeno 1 - 10 of 77 pro vyhledávání: '"R Tato Marinho"'
1
P510 Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis
Autor: S Matos Coelho Bernardo, S Fernandes, J Serrazina, I Rodrigues, I Botto, S Bronze, A R Gonçalves, A Valente, P M D Santos, R Tato Marinho, L Correia
Publikováno v: Journal of Crohn's and Colitis. 17:i640-i641
Background Background: Increasing evidence supports the use of Ustekinumab (USTK) in patients with moderate to severe Crohn’s disease (CD) and Ulcerative colitis (UC). Comparison of USTK against other biologics is still lacking. Methods AIMS: to pe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2eb5993e63ffc5ab1c6e32f49b71a589
https://doi.org/10.1093/ecco-jcc/jjac190.0640
Zobrazit plný text záznamu
4
P653 Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn’s disease
Autor: S R Fernandes, S Bernardo, A Rita Gonçalves, P Moura dos Santos, A Valente, R Tato Marinho, L Correia
Publikováno v: Journal of Crohn's and Colitis. 17:i782-i782
Background increasing evidence support the use of Transmural remission as a treatment target in Crohn’s disease (CD) but few patients can reach it with currently available therapies. Treat-To-Target (T2T) and Tight-Control (TC) strategies may poten
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5514b0aca1f5a76071379bb074e68d63
https://doi.org/10.1093/ecco-jcc/jjac190.0783
Zobrazit plný text záznamu
5
P581 Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
Autor: J Pedro, I Botto, S Fernandes, J Lemos, J Neves, P Campelo, D Carvalho, S Bernardo, A R Gonçalves, A Valente, P Moura Santos, I Rosa, H Tavares de Sousa, J Ramos, J Venâncio, J Leitão, I Claro, L Correia, R Tato Marinho
Publikováno v: Journal of Crohn's and Colitis. 16:i521-i522
Background Endoscopic remission (ER) is currently endorsed as one of the main treatment targets in Crohn’s Disease (CD). In a previous study, we have shown that transmural remission (TR) is associated with better clinical outcomes up to 1-year. It
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a465b7c915b683cc536e7e941e53e6b9
https://doi.org/10.1093/ecco-jcc/jjab232.707
Zobrazit plný text záznamu
6
P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
Autor: I Botto, I Coelho Rodrigues, J Serrazina, S Fernandes, S Bernardo, A R Gonçalves, P Moura Santos, A Valente, L Correia, R Tato Marinho
Publikováno v: Journal of Crohn's and Colitis. 16:i484-i485
Background A large body of evidence demonstrates a significant correlation between week 14 infliximab trough levels (IFXTL) and several clinical outcomes. In patients with low IFXTL at week 14, proactive therapeutic drug monitoring (TDM) may potentia
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4c1b3f4ceeab96829c2696b970d18c6
https://doi.org/10.1093/ecco-jcc/jjab232.659
Zobrazit plný text záznamu
7
P304 Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative Colitis
Autor: J Pedro, I Coelho Rodrigues, I Botto, S Fernandes, S Bernardo, A R Gonçalves, P Moura Santos, A Valente, L Correia, R Tato Marinho
Publikováno v: Journal of Crohn's and Colitis. 16:i332-i333
Background Infliximab is effective as salvage therapy in severe steroid-refractory Ulcerate Colitis. However, up to one third of patients do not respond to this treatment and require surgery. There is still insufficient evidence regarding the benefit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f7ae6a378f6350b2fa270e091cda8a3
https://doi.org/10.1093/ecco-jcc/jjab232.431
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje